Form 4: Viking Therapeutics COO Marianna Mancini Executes Stock Options and Sells Shares Under 10b5-1 Plan
SEC Form 4
Marianna Mancini, Chief Operating Officer of Viking Therapeutics, exercised stock options and sold shares of common stock on May 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On May 1, 2024, Marianna Mancini, the Chief Operating Officer of Viking Therapeutics, executed stock options to acquire a total of 281,425 shares of common stock at prices ranging from $4.68 to $8.52.
- Simultaneously, Mancini sold 25,746 shares at a weighted average price of $76.4045, 26,142 shares at $77.4933, 105,343 shares at $78.6476, 119,946 shares at $79.2945, and 6,248 shares at $80.0753.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 1, 2024.
- Following these transactions, Mancini directly owns 348,508 shares of Viking Therapeutics common stock.
- Mancini also holds options to purchase additional shares of common stock.
Sentiment
Score: 5
Explanation: This Form 4 filing represents routine transactions under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
Executive stock sales are a common occurrence in publicly traded companies, often executed under pre-arranged trading plans like Rule 10b5-1 to avoid accusations of insider trading. The market typically analyzes these transactions to gauge executive sentiment and potential impact on stock price.
Comparison to Industry Standards
- Executive compensation packages often include stock options as a way to align management's interests with those of shareholders.
- Rule 10b5-1 plans are a standard practice among corporate executives to manage their stock transactions in a transparent and compliant manner.
- Comparing Mancini's transactions to those of executives at similar biotech companies (e.g., Madrigal Pharmaceuticals, Intercept Pharmaceuticals) would provide context on the scale and frequency of such activities.
Stakeholder Impact
- Shareholders may interpret the stock sale as a lack of confidence in the company's future performance, although the existence of a 10b5-1 plan mitigates this concern.
- The transactions have no immediate impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2021/01/03 | 25% of the shares subject to the $7.77 option vested or will vest on each one year anniversary of the grant date. |
| 2022/01/04 | One-third of the shares subject to the $5.8 option vested on each one year anniversary of the grant date. |
| 2023/01/03 | 25% of the shares subject to the $4.88 option vested or will vest on each one year anniversary of the grant date. |
| 2024/01/03 | 25% of the shares subject to the $8.52 option vested or will vest on each one year anniversary of the grant date. |
| 2024/02/01 | The Reporting Person adopted a Rule 10b5-1 trading plan. |
| 2024/05/01 | Marianna Mancini exercised stock options and sold shares of common stock. |
| 2030/01/03 | Expiration date of the $7.77 stock option. |
| 2030/03/31 | Expiration date of the $4.68 stock option. |
| 2031/01/04 | Expiration date of the $5.8 stock option. |
| 2032/01/03 | Expiration date of the $4.88 stock option. |
| 2033/01/03 | Expiration date of the $8.52 stock option. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.